Evaluation of a microphysiological human placental barrier model for studying placental drug transfer.

Understanding drug transport across the placental barrier is important for assessing the potential fetal drug toxicity and birth defect risks. Current in vivo and in vitro models have structural and functional limitations in evaluating placental drug transfer and toxicity. Microphysiological systems (MPSs) offer more accurate and relevant physiological models of human tissues and organs on a miniature scale for drug development and toxicology testing. MPSs for the placental barrier have been recently explored to study placental drug transfer. We utilized a multilayered hydrogel membrane-based microphysiological model composed of human placental epithelial and endothelial cells to replicate the key structure and function of the human placental barrier. A macroscale human placental barrier model was created using a transwell to compare the results with the microphysiological model. Placental barrier models were characterized by assessing monolayer formation, intercellular junctions, barrier permeability, and their structural integrity. Three small-molecule drugs (glyburide, rifaximin, and caffeine) that are prescribed or taken during pregnancy were studied for their placental transfer. The results showed that all three drugs crossed the placental barrier, with transfer rates in the following order: glyburide (molecular weight, MW = 494 Da) < rifaximin (MW = 785.9 Da) < caffeine (MW = 194.19 Da). Using non-compartmental analysis, we estimated human pharmacokinetic characteristics based on in vitro data from both MPS and transwell models. While further research is needed, our findings suggest that MPS holds potential as an in vitro tool for studying placental drug transfer and predicting fetal exposure, offering insights into pharmacokinetics.

Developing an In Vitro to In Vivo Extrapolation (IVIVE) Model to Predict Human Milk-to-Plasma Drug Concentration Ratios.

Determining the amount of drug transferred into human milk is critical for benefit-risk analysis of taking medication while breastfeeding. In this study, we developed an in vitro and in vivo extrapolation (IVIVE) model to predict human milk/plasma (M/P) drug concentration ratios. Drug unionized fractions at pH 7.0 (Fni,7.0) and 7.4 (Fni,7.4), drug fractions unbound in human plasma (fup) and milk (fum), and in vitro cell permeability in both directions (efflux ratio, ER) were incorporated into the IVIVE model. A multiple regression Emax model was chosen to predict fum from fup and polar surface area (PSA). A total of 97 drugs with experimental ER from Caco-2 cells were used to test the IVIVE model. The M/P ratios predicted by the IVIVE model had a 1.93-fold geometric mean fold error (GMFE) and 72% of predictions were within two-fold error (Pw2FE), which were superior to the performance of previously reported five models. The IVIVE model showed a reasonable prediction accuracy for passive diffusion drugs (GMFE = 1.71-fold, Pw2FE = 82%, N = 50), BCRP substrates (BCRP: GMFE = 1.91-fold, Pw2FE = 60%, N = 5), and substrates of P-gp and BCRP (GMFE = 1.74-fold, Pw2FE = 75%, N = 8) and a lower prediction performance for P-gp substrates (GMFE = 2.51-fold, Pw2FE = 55%, N = 22). By fitting the observed M/P ratios of 39 P-gp substrates, an optimized ER (1.61) was generated to predict the M/P ratio of P-gp substrates using the developed IVIVE model. Compared with currently available in vitro models, the developed IVIVE model provides a more accurate prediction of the drug M/P ratio, especially for passive diffusion drugs. The model performance is expected to be further improved when more experimental fum and ER data are available.

Fostering multiple healthy lifestyle behaviors for primary prevention of cancer.

The odds of developing cancer are increased by specific lifestyle behaviors (tobacco use, excess energy and alcohol intakes, low fruit and vegetable intake, physical inactivity, risky sexual behaviors, and inadequate sun protection) that are established risk factors for developing cancer. These behaviors are largely absent in childhood, emerge and tend to cluster over the life span, and show an increased prevalence among those disadvantaged by low education, low income, or minority status. Even though these risk behaviors are modifiable, few are diminishing in the population over time. We review the prevalence and population distribution of these behaviors and apply an ecological model to describe effective or promising healthy lifestyle interventions targeted to the individual, the sociocultural context, or environmental and policy influences. We suggest that implementing multiple health behavior change interventions across these levels could substantially reduce the prevalence of cancer and the burden it places on the public and the health care system. We note important still-unresolved questions about which behaviors can be intervened upon simultaneously in order to maximize positive behavioral synergies, minimize negative ones, and effectively engage underserved populations. We conclude that interprofessional collaboration is needed to appropriately determine and convey the value of primary prevention of cancer and other chronic diseases.

Novel on-demand droplet generation for selective fluid sample extraction.

A novel microfluidic device enabling selective generation of droplets and encapsulation of targets is presented. Unlike conventional methods, the presented mechanism generates droplets with unique selectivity by utilizing a K-junction design. The K-junction is a modified version of the classic T-junction with an added leg that serves as the exit channel for waste. The dispersed phase fluid enters from one diagonal of the K and exits the other diagonal while the continuous phase travels in the straight leg of the K. The intersection forms an interface that allows the dispersed phase to be controllably injected through actuation of an elastomer membrane located above the inlet channel near the interface. We have characterized two critical components in controlling the droplet size-membrane actuation pressure and timing as well as identified the region of fluid in which the droplet will be formed. This scheme will have applications in fluid sampling processes and selective encapsulation of materials. Selective encapsulation of a single cell from the dispersed phase fluid is demonstrated as an example of functionality of this design.

Development of a pseudo-uniform structural quantity for use in active structural acoustic control of simply supported plates: an analytical comparison.

Active structural acoustic control has been an area of research and development for over two decades with an interest in searching for an "optimal" error quantity. Current error quantities typically require the use of either a large number of transducers distributed across the entire structure, or a distributed shaped sensor, such as polyvinylidene difluoride. The purpose of this paper is to investigate a control objective function for flat, simply-supported plates that is based on transverse and angular velocity components combined into a single composite structural velocity quantity, termed V(comp). Although multiple transducers are used, they are concentrated at a single location to eliminate the need for transducers spanning most or all of the structure. When used as the objective function in an active control situation, squared V(comp) attenuates the acoustic radiation over a large range of frequencies. The control of squared V(comp) is compared to other objective functions including squared velocity, volume velocity, and acoustic energy density. The analysis presented indicates that benefits of this objective function include control of radiation from numerous structural modes, control largely independent of sensor location, and need to measure V(comp) at a single location and not distributed measurements across the entire structure.

The synergistic effect of sodium chlorite and bromochloroacetic acid on BrO3(-)-induced renal cell death.

Bromate (BrO(3)(-)) is a drinking water disinfection by-product (DBP) that induces renal cell death via DNA damage-dependent and -independent mechanisms. Drinking water contains other DBPs in addition to BrO(3)(-). We tested the effect of two of these, sodium chlorite (NaClO(2)) and bromochloroacetic acid (BCAA), on BrO(3)(-) cytotoxicity in normal rat kidney (NRK) cells. NaClO(2) and BCAA alone induced cytotoxicity at concentrations of over 20ppm, while BrO(3)(-) was only moderately cytotoxic at concentrations of 200ppm. Combining BrO(3)(-) with NaClO(2) or BCAA alone enhanced cytotoxicity 1.5-4 fold. Exposing cells to all three compounds induced synergistic-like increases in cytotoxicity. This effect did not correlate to increases in reactive oxygen species (ROS), even though all three compounds induced ROS formation alone. NaClO(2), but not BCAA, increased BrO(3)(-)-mediated DNA damage as measured by 8-hydroxydeoxyguanosine (8-OHdG) staining. In addition, NaClO(2), but not BCAA, decreased BrO(3)(-)-induced G2/M cell cycle arrest. Both compounds increased apoptosis in the presence of BrO(3)(-) as assessed by annexin V, PI, and DAPI staining. This is in contrast to BrO(3)(-) treatment alone, which induced necrosis. Immunoblot analysis showed that both NaClO(2) and BCAA increased p38 activation; however, consistent with 8-OHdG staining, only NaClO(2) increased BrO(3)(-)-induced histone H2AX phosphorylation, a marker of DNA damage. In contrast, BCAA, but not NaClO(2), increased BrO(3)(-)-induced phosphorylation of p53. These data support the novel finding that mixtures of DBPs increase BrO(3)(-)-induced renal cell death by DNA-dependent and -independent mechanisms, and could alter how the risk of these DBPs towards humans is assessed.

Cellular and molecular mechanisms of bromate-induced cytotoxicity in human and rat kidney cells.

The mechanisms of bromate (BrO(3)(-))-induced toxicity in Normal Rat Kidney (NRK) and human embryonic kidney 293 (HEK293) cells were investigated. BrO(3)(-) (added as KBrO(3)) induced concentration-dependent decreases in 3-(4, dimethylthiazolyl-2)-2,5-diphenyltetrazolium bromide (MTT) staining after 48 h. BrO(3)(-)-induced necrosis based on tandem increases in annexin V and PI staining. Cell cycle analysis demonstrated that BrO(3)(-) also induced G2/M arrest and nuclear fragmentation, prior to alterations in MTT staining or annexin V and PI staining. Immunoblot analysis demonstrated that the G2/M arrest correlated to induction of phosphorylated (p)-p53, p21, cyclin B1 and p-cdc2. Further, BrO(3)(-) induced time-dependent increases in the activity of the mitogen activated protein kinases p38 and ERK1/2. Treatment of cells with the p38 inhibitor SB202190, but not the ERK1/2 inhibitor PD98059, partially reversed BrO(3)(-)-induced G2/M arrest and decreased BrO(3)(-)-induced p-p53, p21 and cyclin B1 expression. In addition, BrO(3)(-) treatment induced reactive oxygen species (ROS) based on increases in CM-H(2)DCFDA fluorescence. The antioxidant ascorbic acid inhibited BrO(3)(-)-induced p38 activation, G2/M arrest, p-p53, p21 and cyclin B1 expression; however, ascorbic acid had no effect on BrO(3)(-)-induced formation of 8-OHdG, a marker of DNA oxidative damage, whose increases preceded cell death by 24h. These data suggest that ROS mediated MAPK activation is involved in the molecular mechanisms of BrO(3)(-)-induced cell cycle arrest, which occurs independently of 8-OH-dG production. The similar mode of action in both NRK and HEK293 cells suggests that the mechanisms of BrO(3)(-)-induced renal cell death are model-independent.

Bayesian analysis of a physiologically based pharmacokinetic model for perchloroethylene in humans.

Perchloroethylene (PCE) is a widely distributed pollutant in the environment, and is the primary chemical used in dry cleaning. PCE-induced liver cancer was observed in mice, and central nervous system (CNS) effects were reported in dry-cleaning workers. To support reconstruction of human PCE exposures, including the potential for CNS effects, an existing physiologically based pharmacokinetic (PBPK) model for PCE in the human (Covington et al., 2007) was modified by adding a brain compartment. A Bayesian approach, using Markov chain Monte Carlo (MCMC) analysis, was employed to re-estimate the parameters in the modified model by combining information from prior distributions for the model parameters and experimental data. Experimental data were obtained from five different human pharmacokinetic studies of PCE inhalation exposures ranging from 150 ppm to as low as 0.495 ppm. The data include alveolar or exhaled breath concentrations of PCE, blood concentrations of PCE and trichloroacetic acid (TCA), and urinary excretion of TCA. The PBPK model was used to predict target tissue dosimetry of PCE and its key metabolite, TCA, during and after the inhalation exposures. Posterior analysis was performed to see whether convergence criteria for each parameter were satisfied and whether the model with posterior distributions may be used to make accurate predictions of human kinetic data. With posteriors, the trend of percent of PCE metabolized in the liver at low concentrations was predicted under different exposure conditions. The 95th percentile for the fraction PCE metabolized at a concentration of 1 ppb was estimated to be 1.89%.